Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism DYRK1A inhibitors(Dual-specificity tyrosine-phosphorylation regulated kinase 1A inhibitors), DYRK1B inhibitors(DYRK-1 beta protein kinase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC22H19F3N8O |
InChIKeyCZWJLLBPWLUINU-UHFFFAOYSA-N |
CAS Registry2426628-29-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | US | 08 Mar 2022 |